Madrigal Pharmaceuticals, Inc. — 2016 Form 10-K
Business context and period: Annual report for the fiscal year ended December 31, 2016; it is not a standalone fourth-quarter report. Madrigal is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, MGL-3196, is being developed for NASH and familial hypercholesterolemia (FH). A reverse merger with Synta closed July 22, 2016; Madrigal was the accounting acquirer, and the combined company adopted the Madrigal name and ticker MDGL.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.9 million | $2.4 million |
| General and administrative expense | $9.3 million | $0.8 million |
| Operating loss | $25.2 million | $3.2 million |
| Net loss | $26.4 million | $6.8 million |
| Net loss per share | $5.07 | $40.03 |
| Net cash used in operating activities | $17.6 million | $3.1 million |
Margins are not meaningful because the company had no revenue. R&D expense increased primarily with advancement of MGL-3196 clinical and preclinical work; G&A rose in part due to merger costs, public-company expenses, and stock compensation. The 2016 net loss included $7.9 million of stock-based compensation, including $5.4 million related to the change-in-control bonus plan. Net interest expense declined to $1.2 million from $3.6 million, largely reflecting waived or non-accruing interest on related-party notes.
At December 31, 2016, cash and cash equivalents were $19.1 million and marketable securities were $21.4 million, for total liquidity of approximately $40.5 million. Current assets were $41.2 million and current liabilities $4.8 million; shareholders’ equity was $36.4 million. The $48.6 million of related-party convertible notes reported at year-end 2015 had converted to equity in connection with the merger; no convertible notes were outstanding at year-end 2016. Cash flows included $14.5 million provided by financing activities, including $6.0 million net ATM equity proceeds and $8.5 million from related-party notes before conversion. The company reported no off-balance-sheet arrangements.
Material changes and developments
- The merger brought $42.6 million in cash, cash equivalents, and marketable securities at closing. Related-party debt and accrued amounts were converted to equity; the lenders also waived $13.7 million of accrued interest under the amended note terms.
- MGL-3196’s Phase 2 NASH trial began in October 2016, planned for approximately 117 patients over 36 weeks. A Phase 2 HeFH trial began in February 2017, planned for approximately 105 patients over 12 weeks.
- In small Phase 1 studies involving 129 subjects, management reported tolerability and reductions in lipid measures, including LDL-C reductions of up to 30%. These early-stage findings do not establish efficacy or safety in larger or longer-term studies.
- As of December 31, 2016, accumulated deficit was $75.3 million. The 2015 auditor report included a going-concern qualification; the 2016 financial statements received an unqualified audit opinion.
Outlook, risks, and unusual items
- Management expected top-line NASH primary-endpoint data near year-end 2017 and NASH biopsy-based secondary-endpoint data in spring 2018. HeFH results were expected near year-end 2017; a small HoFH proof-of-concept study was planned subject to interim HeFH safety and efficacy data, with results expected in 2018.
- Management expected existing liquidity, including first-quarter 2017 ATM proceeds, to fund operations into the second quarter of 2018. Elsewhere, the MD&A states liquidity would fund operations through at least the first quarter of 2018. The filing therefore gives differing runway descriptions. Management anticipated further financing or partnerships, particularly to support Phase 3 NASH development.
- The company expects continued losses and higher development costs. It has no approved products, sales infrastructure, or manufacturing facilities, and relies on third parties for clinical trials and manufacturing. Clinical failure, delays or enrollment problems, adverse events, regulatory requirements, competition, reimbursement, and financing needs are significant risks.
- Disclosure controls and internal control over financial reporting were judged ineffective at year-end because of a material weakness involving earnings-per-share calculations and retrospective share recapitalization. The company had restated interim 2015 and 2016 financial statements; management said it was remediating the weakness and expected remediation in 2017.
- The Roche license includes up to $10 million in remaining development and regulatory milestone payments and single-digit royalties on future net sales. No MGL-3196 product sales had occurred.
Important facts for investors to verify
- Whether clinical trials met endpoints and timelines, and whether longer-term safety findings support the early Phase 1 profile.
- Actual cash runway and financing needs; reconcile the filing’s first-quarter versus second-quarter 2018 runway statements and account for subsequent ATM issuance.
- Progress in remediating the material weakness and whether future filings avoid EPS or recapitalization errors.
- Remaining Roche milestone obligations, potential royalties, and the terms and dilution effects of future financing.
- Whether management’s stated development plans, including potential Phase 3 funding and the planned HoFH study, proceeded as described.